InVitae (NVTA) Misses Q4 EPS by 16c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/24/2026
- Wall St edges higher as investors juggle earnings, Mideast risks and tariffs
- Elon Musk’s trillion-dollar meltdown: How SpaceX and Tesla erased $700 billion
- Intel jumps 10% after AI-fueled quarter crushes estimates, upbeat outlook
- Oil down more than 4% on profit taking, report of China-backed push to end US-Iran fighting
- Why Meta, Microsoft, and Nvidia are championing open-weight AI
- Americold to wind down Ahold Delhaize facilities, take $305M charge
- AMD (AMD) PT Raised to $1,250 at Baird
- Pakistan, Iran explore path towards new talks with US in a China-initiated push, sources say
- Wall St falls as tech earnings spark AI spending worries and oil hits $100
- Did Google and Tesla just break AI trade’s bull case?
Invitae Reports $460.4 Million in Annual Revenue Driven by 1.17 Million in Billable Volume in 2021
February 24, 2022 4:05 PM ESTSAN FRANCISCO, Feb. 24, 2022 /PRNewswire/ -- Invitae (NYSE: NVTA), a leading medical genetics company, today announced financial and operating results for the fourth quarter and year ended December 31, 2021.
